Latest News - Glaucoma

Wednesday, February 14, 2018 | Glaucoma

Study: Trabeculectomy After Failed Glaucoma Drainage Device Surgery

Trabeculectomy after failed glaucoma drainage device (GDD) is often thought of as a poor choice due to the possibility of violated conjunctiva leading to failure of the trabeculectomy. Thus, no large …

Read the full story

Tuesday, February 13, 2018 | Glaucoma, Medical Studies

Neutron Study of Glaucoma Drugs Offers Clues About Enzyme Targets for Aggressive Cancers

New insights from neutron analysis of glaucoma drugs and their enzyme target may help scientists design drugs that more effectively target aggressive cancers. A team of researchers led by the Dep…

Read the full story

Friday, February 09, 2018 | Glaucoma

NEI Support Paved Early Pathway for Novel Glaucoma Therapies

The recent approval of two novel medications for glaucoma -- the first new medications for the disorder in nearly 18 years -- are fruit born from decades of foundational scientific research suppor…

Read the full story

Friday, February 09, 2018 | Glaucoma

Q Biomed Signs Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma

Q BioMed has announced an exclusive option agreement with Washington University in St. Louis. Under the agreement granting the exclusive right to license the technology, Q BioMed will evaluate the fea…

Read the full story

Thursday, February 08, 2018 | Glaucoma, Glaukos Corporation

Study: Glaukos iStent Reduced IOP and Lowered Medication Burden in Patients with Severe Glaucoma

Glaukos announced that a study published in the January 2018 issue of the Journal of Glaucoma showed that a single iStent Trabecular Micro-Bypass Stent implanted during cataract surgery in patients wi…

Read the full story

Friday, February 02, 2018 | Glaucoma, Akorn Pharmaceuticals

Notification of Availability of Preservative-Free Cosopt PF

Days after being placed on the FDA shortage list, Akorn, the maker of glaucoma drug Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution), noted that Cosopt PF 2%/0.5% is "widely…

Read the full story

Wednesday, January 31, 2018 | Earnings & Financials, Glaucoma

InFocus Capital Partners Completes Series A Investment in Qura

InFocus Capital Partners, an investment firm specializing in the identification and commercialization of ophthalmic health care innovations, has provided a Series A round of funding for Qura Inc. to a…

Read the full story

Wednesday, January 10, 2018 | Clinical Trials, Glaucoma, Glaukos Corporation, MIGS

Glaukos' iDose Travoprost Achieves Sustained IOP Reduction and Favorable Safety Profile in 12-Month Interim Cohort

Glaukos announced that its travoprost Intraocular Implant with the iDose delivery system continued to provide sustained reduction in IOP in a 12-month interim cohort of patients in its U.S. investigat…

Read the full story

Wednesday, January 03, 2018 | Glaucoma, Glaukos Corporation

Glaukos Submits IDE Application to FDA to Study iStent infinite Trabecular Micro-Bypass System

Glaukos announced that it has submitted an investigational device exemption (IDE) application to the FDA seeking authorization to study its iStent infinite Trabecular Micro-Bypass System. The iSten…

Read the full story

Wednesday, January 03, 2018 | Glaucoma, Glaukos Corporation, MIGS

Glaukos Submits IDE Application to FDA to Study iStent infinite Trabecular Micro-Bypass System

Glaukos announced that it has submitted an investigational device exemption (IDE) application to the FDA seeking authorization to study its iStent infinite Trabecular Micro-Bypass System. The iSte…

Read the full story

Wednesday, December 27, 2017 | Glaucoma, Glaukos Corporation

Glaukos Announces Submission of Premarket Approval Application for the iStent Inject Trabecular Micro-Bypass

Glaukos announced that it has submitted a premarket approval (PMA) application to the FDA for the iStent inject Trabecular Micro-Bypass Stent. The iStent inject is designed to improve aqueous humor…

Read the full story

Monday, December 18, 2017 | FDA Approval/Clearance, Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Receives Long-Awaited FDA Approval of Glaucoma Treatment Rhopressa

After setbacks and years of clinical testing, Aerie Pharmaceuticals has received FDA approval of Rhopressa (netarsudil ophthalmic solution .02%) for the lowering of elevated IOP in patients with …

Read the full story

Friday, December 15, 2017 | Glaucoma, Medical Studies

Brewing Health Benefits: Hot Tea May Lower Glaucoma Risk

Hot tea may do more than warm your insides: Drinking at least one cup of caffeinated tea a day may lower a person's risk for glaucoma, a new study suggests, as reported in Live Science. Researc…

Read the full story

Friday, November 17, 2017 | Clinical Trials, Glaucoma, Implandata Ophthalmic Products, IOP

Successful First-in-Human Testing of Implandata’s Next-Generation Eyemate Micro-Sensor for Improved Monitoring of Glaucoma Patients

Implandata Ophthalmic Products reported that its next-generation Eyemate micro-sensor implant for intraocular placement has successfully passed first-in-human validation.  “Thi…

Read the full story

Saturday, November 11, 2017 | Clinical Trials, Glaucoma, Ivantis

Ivantis FDA Clinical Trial of the Hydrus Microstent for Minimally Invasive Glaucoma Surgery Meets Endpoints, Exceeds Outcomes of Past MIGS Trials

Ivantis announced that the HORIZON pivotal study has met both the 2-year primary and secondary pre-established endpoints. Outcomes exceed those of any MIGS pivotal trial to date. Ivantis previously an…

Read the full story
Load More